SUMMARY OF MEDTECH'S LIQUIDITY CONTRACT
WITH ODDO CORPORATE FINANCE

Montpellier, France, January 12, 2016

Pursuant to the liquidity contract granted to Oddo Corporate Finance regarding Medtech shares, the following resources were listed in the liquidity account as of December 31, 2015:

- 14,052 Medtech shares
- 168,343.29 Euros

As of June 30, 2015, the most recent update, the following resources had been allocated to the liquidity account:

- 6,360 Medtech shares
- 368,737.44 Euros

About MEDTECH

Founded in 2002 by Bertin NAHUM and based in Montpellier, MEDTECH is a European specialist in the design, development and marketing of innovative robotic appliances to assist surgeons during their medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less-invasive treatment.

In 2007, MEDTECH developed ROSA™, an innovative technological device devoted to brain surgery procedures. ROSA™ has been approved in Europe, the United States and Canada.

In 2013 MEDTECH received the "European Company of the Year Award" in the "robotic neurosurgery" category from Frost & Sullivan.

In July 2014, MEDTECH obtained the CE marking for its new product ROSA™ Spine, a robotic- assistive device for minimally invasive surgery of the spine.

In November 2015, MEDTECH was honored by Deloitte In Extenso for its excellent performance in the Technology Fast 50 Mediterranean Awards, in the "listed company" category.

In 2015 MEDTECH received the "2016 Company of the Year Award" in the "robotic neurosurgery" category from Frost & Sullivan.

In January 2016, MEDTECH obtained the FDA clearance for its new product, ROSA™ Spine, a robotic-assistive device for minimally invasive surgery of the spine.

CONTACT MEDTECH	INVESTORS	PRESS	
Christophe Sibillin	Corinne Puissant	Alexandra Prisa (EU)	Joanna Zimmerman (US)
Chief Financial Officer	Tel : +33 (0)1 53 67 36 77	Tel. : +33(0)1 53 67 36 90	Tel : +1 646-536-7006
Tel : +33 (0)4 67 10 77 40	cpuissant@actus.fr	aprisa@actus.fr	jzimmerman@theruthgroup.com